VERV — Verve Therapeutics Share Price
Last trade - 00:00- $462.65m
- -$61.63m
- $32.33m
- 46
- 20
- 51
- 33
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.94 | ||
| Price to Tang. Book | 0.94 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 14.31 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -37.83% | ||
| Return on Equity | -36.36% | ||
| Operating Margin | -707.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 1.94 | 11.76 | 32.33 | 24.15 | 12.91 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Verve Therapeutics, Inc. is a clinical-stage company. The Company is focused on developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The Company’s lead programs include VERVE-102, VERVE-201, and VERVE-301, which target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE- 201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels.
Directors
- Burt Adelman NEC (69)
- Andrew Ashe PRE (54)
- Sekar Kathiresan CEO (49)
- Allison Dorval CFO (46)
- Andrew Bellinger CSO (43)
- Margaret Beaudoin VFN (52)
- John Evans DRC (44)
- Michael Maclean IND (55)
- Sheila Mikhail IND (54)
- Krishna Yeshwant IND (43)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 9th, 2018
- Public Since
- June 17th, 2021
- No. of Shareholders
- 23
- No. of Employees
- 274
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 89,143,237
- Address
- 201 Brookline Avenue, Suite 601, BOSTON, 02215
- Web
- https://www.vervetx.com/
- Phone
- +1 9785013026
- Auditors
- Ernst & Young LLP
Upcoming Events for VERV
Similar to VERV
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
As of Today at 23:58 UTC, shares in Verve Therapeutics are trading at $5.19. This share price information is delayed by 15 minutes.
Shares in Verve Therapeutics last closed at $5.19 and the price had moved by -15.61% over the past 365 days. In terms of relative price strength the Verve Therapeutics share price has underperformed the S&P500 Index by -23.9% over the past year.
The overall consensus recommendation for Verve Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreVerve Therapeutics does not currently pay a dividend.
Verve Therapeutics does not currently pay a dividend.
Verve Therapeutics does not currently pay a dividend.
To buy shares in Verve Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.19, shares in Verve Therapeutics had a market capitalisation of $462.65m.
Here are the trading details for Verve Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: VERV
Based on an overall assessment of its quality, value and momentum Verve Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Verve Therapeutics is $25.17. That is 384.97% above the last closing price of $5.19.
Analysts covering Verve Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.73 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Verve Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -12.08%.
As of the last closing price of $5.19, shares in Verve Therapeutics were trading -11.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Verve Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Verve Therapeutics' management team is headed by:
- Burt Adelman - NEC
- Andrew Ashe - PRE
- Sekar Kathiresan - CEO
- Allison Dorval - CFO
- Andrew Bellinger - CSO
- Margaret Beaudoin - VFN
- John Evans - DRC
- Michael Maclean - IND
- Sheila Mikhail - IND
- Krishna Yeshwant - IND